Article Published in The Lancet Gastroenterology & Hepatology Highlighting Safety and Preliminary Effects of KAN-101 in Celiac Disease in its ACeD Phase 1 Clinical Trial

The Lancet Gastroenterology & Hepatology has published clinical data on KAN-101 from the Phase 1 ACeD (Assessment of KAN-101 in Celiac Disease) Trial, which support the favorable safety of KAN-101 and signals of dose-dependent reactivity to gluten and induction of immune tolerance in patients with celiac disease.